Nucleoside analogue 2’-C-methylcytidine inhibits hepatitis E virus replication but antagonizes ribavirinReport as inadecuate




Nucleoside analogue 2’-C-methylcytidine inhibits hepatitis E virus replication but antagonizes ribavirin - Download this document for free, or read online. Document in PDF available to download.

Archives of Virology

pp 1–8

First Online: 16 June 2017Received: 20 January 2017Accepted: 03 June 2017DOI: 10.1007-s00705-017-3444-8

Cite this article as: Qu, C., Xu, L., Yin, Y. et al. Arch Virol 2017. doi:10.1007-s00705-017-3444-8

Abstract

Hepatitis E virus HEV infection has emerged as a global health issue, but no approved medication is available. The nucleoside analogue 2’-C-methylcytidine 2CMC, a viral polymerase inhibitor, has been shown to inhibit infection with a variety of viruses, including hepatitis C virus HCV. Here, we report that 2CMC significantly inhibits the replication of HEV in a subgenomic replication model and in a system using a full-length infectious virus. Importantly, long-term treatment with 2CMC did not result in a loss of antiviral potency, indicating a high barrier to drug resistance development. However, the combination of 2CMC with ribavirin, an off-label treatment for HEV, exerts antagonistic effects. Our results indicate that 2CMC serves as a potential antiviral drug against HEV infection.





Author: Changbo Qu - Lei Xu - Yuebang Yin - Maikel P. Peppelenbosch - Qiuwei Pan - Wenshi Wang

Source: https://link.springer.com/



DOWNLOAD PDF




Related documents